Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, ...

If you have dry age-related macular degeneration, your central vision may end up blurry, distorted or dim.

Discover the latest breakthroughs in the fight against dry, age-related macular degeneration. Learn about the first approved ...

Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for ...

KTALnews.com (KTAL/KMSS) – A wireless retinal implant is helping restore vision in patients with advanced age-related macular ...

AI-powered wearable glasses empower individuals living with age-related macular degeneration (AMD) and other retinal ...

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05) Potential 2X treatment benefit compared to 15% and 22% ...

Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and ...

Researchers have found in a new study that advanced periodontal inflammation (stage III–IV) may cause degenerative changes in ...